Using AI scans to predict long-term eye treatment results
Part of Eyes & vision clinical trials.
This trial uses advanced imaging and artificial intelligence to predict how well patients with myopic macular neovascularization (a complication of severe nearsightedness) will respond to anti-VEGF injections over time. The goal is to identify who will benefit most from ongoing treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have severe nearsightedness (over -6.0 diopters) or a very long eyeball (over 26.5 mm).
- You must have myopic changes in your macula (the central part of your retina).
- You must have an active, treatment-naïve CNV (new, untreated abnormal blood vessels in your eye).
- You must have had a full eye exam including special scans (OCT, OCTA, and dye test).
- You must not have CNV caused by other conditions like age-related macular degeneration or certain other eye diseases.
- Your OCTA images must be clear and free of artifacts for analysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the treatment for a condition called myopic choroidal neovascularization (abnormal blood vessels in the central vision due to severe nearsightedness) affects patients' daily lives. It aims to understand the burden of treatment on people with this eye problem.
This trial uses special eye scans to predict how well anti-VEGF treatment will work for patients with a type of age-related macular degeneration called nAMD. It aims to help doctors better understand who will benefit most from this treatment.
This Phase 4 study tests an artificial-intelligence (AI) system used in real-world care for people with “wet” age-related macular degeneration. The goal is to help doctors monitor and treat the eye more accurately and safely over time.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This trial uses artificial intelligence to analyze eye images and help doctors diagnose eye diseases. It looks at images from routine care to train and test the AI system.
This trial tests a combination of two treatments—a heat procedure and a medication injection—to reduce abnormal blood vessel growth on the clear front surface of your eye (cornea). The goal is to improve your vision and prevent further damage.
Hear when a new Myopic Choroidal Neovascularization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.